Quick Answer
Seres Therapeutics, Inc. reported Research And Development Expense of $49.06 million for the year ending 2025.
- Seres Therapeutics, Inc. showed a decrease of -24.1% in Research And Development Expense from 2024 to 2025.
- This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Seres Therapeutics, Inc.'s Research And Development Expense has grown by 921.0%.
- Historical annual values: Fiscal year 2025: $49.06 million | Fiscal year 2024: $64.60 million | Fiscal year 2023: $117.60 million | Fiscal year 2022: $109.65 million | Fiscal year 2021: $141.89 million | Fiscal year 2020: $90.57 million | Fiscal year 2019: $80.14 million | Fiscal year 2018: $95.96 million | Fiscal year 2017: $89.46 million | Fiscal year 2016: $81.99 million | Fiscal year 2015: $38.10 million | Fiscal year 2014: $10.72 million | Fiscal year 2013: $4.81 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: